Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 329 - 336 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC2167 | VX-680 (MK-0457,Tozasertib) |
|
High affinity and selective Aurora kinase inhibitor (Ki values are 0.6, 5 and 18 nM for Aurora A, Aurora C and Aurora B, respectively). Also exhibits affinity for FLT-3 and Abl. Exhibits selectivity for Aurora kinase over 190 other protein kinases. Inhibits proliferation and induces apoptosis in a number of cancer cell lines in vitro. Reduces tumor size in leukemia and colon cancer cell xenografts in mice.
|
|
| BCC2169 | ZM 447439 |
|
Novel, selective ATP-competitive inhibitor of Aurora B kinase <em>in vitro</em> (IC<sub>50</sub> values are 50, 250 and 1000 nM for Aurora B, C and A kinases respectively). Selective over a range of other kinases including cdk1 and PLK1 (IC<sub>50</sub> > 10 <span class='symbol'>μ</span>M). Inhibits cell division and displays selective toxicity towards proliferating tumor cells versus non-dividing cells.
|
|
| BCC2174 | Hesperadin |
|
ATP-competitive inhibitor of Aurora B kinase (IC<sub>50</sub> = 250 nM). Prevents chromosome alignment and segregation; also induces polyploidy and prevents histone H3-Ser10 phosphorylation. Overrides the spindle assembly checkpoint and induces mitotic exit in monastrol- and taxol -treated HeLa cells.
|
|
| BCC2177 | SNS-314 Mesylate |
|
Potent, ATP-competitive Aurora kinase inhibitor (IC<sub>50</sub> values are 3, 9 and 31 nM for Aurora C, A and B, respectively). Exhibits both <em>in vitro</em> and <em>in vivo</em> activity against human cancer cell lines and tumor xenograft models. Displays additive antiproliferative effects in combination with chemotherapeutics such as carboplatin, gemcitabine and 5-fluorouracil.
|
|
| BCC2182 | Aurora A Inhibitor I |
|
Potent and selective inhibitor of Aurora kinase A (IC<sub>50</sub> = 3.4 nM); exhibits 1000-fold selectivity for Aurora kinase A over Aurora kinase B. Displays antiproliferative activity in HCT116 and HT29 cells (IC<sub>50</sub> values are 0.19 and 2.9 <span class='symbol'>μ</span>M respectively).
|
|
| BCC2184 | PF-03814735 |
|
ATP-competitive inhibitor of Aurora kinases A and B (IC50 values are 0.8 and 5 nM for recombinant Aurora B and Aurora A, respectively). Inhibits phosphorylation of Aurora B, histone H3 and Aurora A in cultured MDA-MB-231 cells (IC50 values are approximately 20, 50 and 150 nM respectively). Shown to block cytokinesis; inhibits cellular proliferation in several human tumor cell lines, including HCT-116, HL-60, A549 and H125, and in human xenograft mouse models. Orally available.
|
|
| BCC2188 | CCT137690 |
|
Potent inhibitor of Aurora kinases (IC<sub>50</sub> values are 0.015, 0.019 and 0.025 <span class='symbol'>μ</span>M at Aurora A, Aurora C and Aurora B respectively). Displays antiproliferative activity in a range of human tumor cell lines. Orally bioavailable.
|
|
| BCC2191 | AZD1480 |
|
Potent and selective JAK2 inhibitor (IC50 < 3 nM). Exhibits >50-fold selectivity for JAK2 over JAK3. Exhibits antitumor effects and inhibits formation of lung metastases in a mouse renal cancer model. Also inhibits STAT3 signaling, tumor angiogenesis and myeloid cell migration in vivo.
|
|